BerGenBio ASA announced that the Trial Steering Committee of the EU-SolidAct has recommended to discontinue the bemcentinib study arm in the Ph2b EU-SolidAct platform study in hospitalized COVID-19 patients due to a lack of eligible patients. This recommendation is supported by BerGenBio. The regulatory sponsor of the study, Oslo University Hospital, will enact this decision.

In April 2023, BerGenBio announced that the parties unanimously decided to pause the bemcentinib study arm due to a lack of eligible patients. The parties also agreed that a potential resumption of the study arm would be subject to eligible patients being available. BerGenBio will not incur any financial impact from the closure of the bemcentinib study arm.